Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy.
Kanai
M
M
Matsumoto
S
S
Nishimura
T
T
Matsumura
Y
Y
Hatano
E
E
Mori
A
A
Masui
T
T
Kawaguchi
Y
Y
Nakamura
E
E
Tada
S
S
Kitano
T
T
Ishiguro
H
H
Yanagihara
K
K
Chiba
T
T
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D003907:Dexamethasone / Q000627:therapeutic use*; D005076:Exanthema / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D011292:Premedication / Q000379:methods*; D055502:Secondary Prevention; D000093542:Gemcitabine
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D003907:Dexamethasone; D000093542:Gemcitabine